drugset / Trial / NCT00834756

Azithromycin 600 Mg Tablets, Fasting

NCT00834756

Phase 1 Completed 36 enrolled Teva Pharmaceuticals USA
RandomizedCrossoverOpen-labelOther

Summary

The objective of this randomized, single-dose, two-way crossover evaluation is to compare the relative bioequivalence of a test azithromycin formulation (TEVA Pharmaceuticals USA) to an equivalent oral dose of the commercially available azithromycin (Zithromax®, Pfizer, Inc.) in a test population of 36 adult subjects under fasting conditions.

Timeline

Start
2002-09
Primary completion
2002-10
Completion
2002-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Azithromycin Small molecule 600 mg Oral

Indications

No indication recorded.